rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Nonprescription drugs
    sub title: considerations regarding a behind-the-counter drug class : report to congressional requesters
  title info:
    title: Nonprescription drugs
    sub title: considerations regarding a behind the counter drug class
  title info:
    title: Considerations regarding a behind-the-counter drug class
  title info:
    title: Behind-the-counter drug class
  name:
    name part: United States
    name part: Government Accountability Office.
    role:
      role term: creator
  type of resource: text
  genre: bibliography
  origin info:
    place:
      place term: dcu
    date issued: 2009
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: remote
    extent: ii, 54 pages : digital, PDF file.
  abstract: In the United States, most nonprescription drugs are available over-the-counter (OTC) in pharmacies and other stores. Experts have suggested that drug availability could be increased by establishing an additional class of nonprescription drugs that would be held behind the counter (BTC) but would require the intervention of a pharmacist before being dispensed; a similar class of drugs exists in many other countries. Although the Food and Drug Administration (FDA) has not developed a detailed proposal for a BTC drug class, it held a public meeting in 2007 to explore the public health implications of BTC drug availability. GAO was asked to update its 1995 report, Nonprescription Drugs: Value of a Pharmacist-Controlled Class Has Yet to Be Demonstrated (GAO/PEMD-95-12). Specifically, GAO is reporting on (1) arguments supporting and opposing a U.S. BTC drug class, (2) changes in drug availability in five countries since 1995 and the impact of restricted nonprescription classes on availability, and (3) issues important to the establishment of a BTC drug class. GAO reviewed documents and consulted with pharmaceutical experts. To examine drug availability across countries, GAO studied five countries it had reported on in 1995 (Australia, Italy, the Netherlands, the United Kingdom, and the United States) and determined how 86 drugs available in all five countries were classified in each country.
  note: Title from title screen (viewed on Mar. 24, 2009).
  note: "February 2009."
  note: "GAO-09-245."
  note: Electronic resource.
  note: System requirements: Adobe Acrobat Reader.
  note: Mode of access: World Wide Web from GAO web site. Address as of 3/24/09: http://www.gao.gov/new.items/d09245.pdf ; current access available via PURL.
  note: Includes bibliographical references.
  subject:
    geographic code: n-us---
  subject:
    topic: Drugs, Nonprescription
  subject:
    topic: Drugs, Nonprescription
    topic: Government policy
    geographic: United States
  subject:
    topic: Pharmaceutical policy
    geographic: United States
  classification: GA 1.13:GAO-09-245
  identifier: https://purl.fdlp.gov/GPO/LPS113194
  record info:
    record content source: DID
    record creation date: 090324
    record change date: 20211202191732.0
    record identifier: in00002460708